STAT3 antisense oligonucleotide AZD9150 in a subset of patients with heavily pretreated lymphoma: results of a phase 1b trial

STAT3 antisense oligonucleotide AZD9150 in a subset of patients with heavily pretreated lymphoma: results of a phase 1b trial

Abstract Background The Janus kinase (JAK) and signal transduction and activation of transcription (STAT) signaling pathway is an attractive target in multiple cancers. Activation of the JAK-STAT pathway is important in both tumorigenesis and activation of immune responses. In diffuse large B-cell l...

Full description

Bibliographic Details
Main Authors: Matthew J. Reilley, Patricia McCoon, Carl Cook, Paul Lyne, Razelle Kurzrock, Youngsoo Kim, Richard Woessner, Anas Younes, John Nemunaitis, Nathan Fowler, Michael Curran, Qinying Liu, Tianyuan Zhou, Joanna Schmidt, Minji Jo, Samantha J. Lee, Mason Yamashita, Steven G. Hughes, Luis Fayad, Sarina Piha-Paul, Murali V. P. Nadella, Xiaokun Xiao, Jeff Hsu, Alexey Revenko, Brett P. Monia, A. Robert MacLeod, David S. Hong
Format: Article
Language:English
Published: BMJ Publishing Group 2018-11-01
Series:Journal for ImmunoTherapy of Cancer
Subjects:
STAT3
Anti-sense oligonucleotide
Diffuse large B-cell lymphoma
DLBCL
Clinical trial
Immunotherapy
Online Access:http://link.springer.com/article/10.1186/s40425-018-0436-5

Internet

http://link.springer.com/article/10.1186/s40425-018-0436-5

Similar Items